CorInnova, Inc.

Johnson & Johnson Innovation JLABS @ TMC, Houston.
With a lead investment from the UK-based Wellcome Trust, a premier international medical foundation, CorInnova is developing a non-blood contacting cardiac assist device. CorInnova’s device is a transformative biventricular device to treat acute heart failure. The technology will create a new paradigm for treatment. The device is designed to eliminate 40% of the adverse events associated with existing cardiac assist technologies, and may expand eligible patients by 3 to 4 times. The device may reverse the progression of HF, a blockbuster application. The device deploys minimally invasively into the pericardial sac in under 30 seconds, and has shown the ability to increase cardiac output by up to 50%. Addressable markets are up to $8 billion.

Company’s Keywords:

heart failure, minimally invasive, biventricular cardiac assist device, nonblood contacting, cardiovascular, congestive heart failure, medical device, active implantable medical device, cardiac assist, heart assist, soft robotics, mechanical circulatory support